Brief: Alphamab Oncology Announces IND Approval For Phase II Clinical Trial Of KN046 In U.S.
08/03/2021 14:56
March 8 (Reuters) - Alphamab Oncology 9966.HK :
* INVESTIGATIONAL NEW DRUG APPROVAL FOR PHASE II CLINICAL
TRIAL IN
U.S. FOR KN046 RECEIVED FROM FDA
Source text for Eikon: urn:newsml:reuters.com:*:nHKS2z2Dcz
Further company coverage: 9966.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)